TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
1 report, 1 independent
Updated Aug 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Incyte
American pharmaceutical company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
Related events
- Wellington Management reduced its stock holdings in Incyte, alongside sales by EVP Patrick Mayes and insider Pablo Cagnoni.
- Incyte stock is trading on the Nasdaq exchange, with its performance being discussed in a bullish light due to strong fundamentals and earnings momentum.
- TD Cowen upgraded shares of Carnival Corp. to a strong-buy rating on September 11, 2026.
- Truist Financial and TD Cowen provided rating and price targets for SiBone shares.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.